Bionano Genomics Inc (BNGO) Actualités

Bionano Announces Effective Date of Reverse Stock Split

SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO)(the “Company”) today...

Form 8-K - Current report

Bionano Announces Use of OGM in Preimplantation Genetic Testing as Part of Successful Live Birth to a Couple Experiencing Recurrent Pregnancy Loss

OGM uniquely identified a complex chromosomal rearrangement missed by classical cytogenetics, helping clinical...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Bionano Reports Preliminary Fourth Quarter and Full-Year 2024 Results

Preliminary Q4 2024 revenue expected to be between $7.9 and $8.1 million, which would represent an estimated...

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]

Bionano Announces Publication Showing that OGM Identifies Variant that Indicates Use of Proven Therapy in Acute Promyelocytic Leukemia

A case study published by researchers at Johns Hopkins University showed that optical genome mapping (OGM...

Bionano Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it...

Form 8-K - Current report

Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway

SAN DIEGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it...